Live Webinar: Association of COVID-19 inflammation with activation of the C5a-C5aR1 axis

Monday 22nd June 2020

Eric Vivier provides a longitudinal analysis of immune responses, including immune cell phenotyping and assessments of the soluble factors present in the blood and broncho-alveolar lavage fluid (BALF) of patients at various stages of COVID-19 severity: paucisymptomatic, pneumonia and acute respiratory distress syndrome (ARDS).

He reports an increase in soluble C5a levels proportional to COVID-19 severity and high levels of C5aR1 expression in blood and pulmonary myeloid cells, supporting a role for the C5a-C5aR1 axis in the pathophysiology of ARDS.

Anti-C5aR1 therapeutic monoclonal antibodies (mAbs) prevented C5a-mediated human myeloid cell recruitment and activation, and inhibited acute lung injury (ALI) in human C5aR1 knockin mice.

These results support C5a-C5aR1 axis blockade as a means of limiting myeloid cell infiltration in damaged organs and preventing the excessive lung inflammation and endothelialitis associated with ARDS in COVID-19 patients.

Join the webinar: IUIS-Frontiers Webinar Series on COVID-19


Event Details


Upcoming Events

The 49th Annual Scientific Meeting of the Australian and New Zealand Society for Immunology, ASI 2021

Wednesday 8th December 2021

5th Antigen-Specific Immune Tolerance Summit

Wednesday 26th January 2022

7th Annual BSI Conference: Science & Society

Saturday 26th February 2022

31st Annual Meeting of the Society for Virology

Wednesday 30th March 2022 at Munich, Germany

IPIC 5th Edition

Wednesday 27th April 2022 at Centro de Congressos do Algarve

IMMUNOLOGY 2022

Friday 6th May 2022

2022 CIMT Annual Meeting

Tuesday 10th May 2022

ALACI 2022

Monday 6th June 2022 at Varadero, Cuba

Cytokines 2022: 10th Annual Meeting of the International Cytokine & Interferon Society

Tuesday 20th September 2022